Bromfenac-d4 sodium

Modify Date: 2024-01-09 11:28:51

Bromfenac-d4 sodium structure	Common Name	Bromfenac-d4 sodium
	CAS Number	2749400-35-7	Molecular Weight	360.17
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₅H₇D₄BrNNaO₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bromfenac-d4 sodium

Bromfenac-d4 (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].

Name	Bromfenac-d4 sodium

Description	Bromfenac-d4 (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> COX
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Schechter BA, et, al. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019 Aug 1; 13:1439-1460. [3]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85. [4]. Chen K, et, al. Bromfenac Inhibits TGF-β1-Induced Fibrotic Effects in Human Pterygium and Conjunctival Fibroblasts. Invest Ophthalmol Vis Sci. 2019 Mar 1; 60(4): 1156-1164.

Molecular Formula	C₁₅H₇D₄BrNNaO₃
Molecular Weight	360.17

Bromfenac-d4 sodium

Use of Bromfenac-d4 sodium

Names

Bromfenac-d4 sodium Biological Activity

Chemical & Physical Properties